NL-OMON45710已完成不适用
Male fertility after treatment with radioiodine for differentiated thyroid carcinoma - Male fertility after DTC
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •All males (age * 18) that were diagnosed with DTC and treated with radioiodine after 2000 that are at least *2 years after their last treatment with a high cumulative dose of radioiodine (* 100 mCi) are eligible for inclusion for this study
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •- Use of drugs that interact with semen quality
- •- Use of anabolic steroids
- •- Fever (body temperature >38°C) in the three months before semen analysis
- •- Gonadal/testicular diseases or treatments that are associated with impairment of semen quality
- •- Active disease state (widespread metastases, under active treatment for DTC or active treatment with systemic therapy/radiotherapy).
- •- Attained age older than 60 years.
- •- I-131 only administered combined with use of recombinant human TSH (rhTSH) and no thyroid hormone withdrawal therapy before I-131 administrations;
- •- Non-compliance of thyroid hormone substitution, resulting in several measurements of
- •TSH >10 mU/l in the last year before evaluation.
研究者
相似试验
招募中
不适用
Mannelijke vruchtbaarheid na een hoge dosis radioactief jodium voor de behandeling van gedifferentieerd schildklierkankerNL-OMON23189niversity Medical Center Groningen100
已完成
1 期
Clinical study of infertility treatment using platelet rich plasma (PRP) to endometrium.SterilityJPRN-UMIN000030493CONCIDE(Correct health Information for Cooperative and innovative development of society)40
进行中（未招募）
1 期
Addition of Apalutamide to current standard therapy (hormonal therapy and radiation therapy) in patients with prostate cancer.EUCTR2018-000899-15-PLEuropean Organisation for Research and Treatment of Cancer (EORTC)990
进行中（未招募）
1 期
Addition of Apalutamide to current standard therapy (hormonal therapy and radiation therapy) in patients with prostate cancer.Intermediate and Limited High Risk Localized Prostate CancerMedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000899-15-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)990
进行中（未招募）
1 期
Addition of Apalutamide to current standard therapy (hormonal therapy and radiation therapy) in patients with prostate cancer.EUCTR2018-000899-15-ESEuropean Organisation for Research and Treatment of Cancer (EORTC)990